Coya Therapeutics

Coya is developing disruptive, first in class, autologous regulatory T-cell (Treg) and allogeneic exosome therapies - leveraging the seminal discoveries from the laboratory of Stanley Appel M.D., in which dysfunctional Tregs modulate neurodegenerative and autoimmune diseases.